Bergen, Norway, 14 May 2018 – The Annual General Meeting of BerGenBio ASA was held at Møllendalsbakken 9, 5009 Bergen, on 14 May 2018. All proposals were resolved as presented in the notice convening the annual general meeting distributed on 23 April 2018, as further set out in the minutes from the annual general meeting … Read more
Bergen, Norway, 08 May 2018- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the first quarter 2018 on Tuesday, 15 May 2018. A presentation by BerGenBio’s senior management team will … Read more
Bergen, Norge, 18. april 2018 – BerGenBio ASA (OSE:BGBIO), et onkologisk bioteknologiselskap i klinisk fase som utvikler ‘first-in-class’ hemmere av AXL kinase mot flere krefttyper, opplyser at lovende prekliniske data med BerGenBios ledende AXL-hemmer bemcentinib (tidligere BGB324) ble presentert på American Association of Cancer Research (AACR) sitt årsmøte for 2018 i perioden 14-18. april i … Read more
Bergen, Norway, 18 April 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with its lead AXL inhibitor bemcentinib (formerly BGB324) has been presented in a poster at the 2018 American Association for Cancer Research (AACR) Annual Meeting on … Read more
Bemcentinib active in pre-clinical models of IPF and NASH IPF and cirrhotic NASH patients with aggressive disease identified by AXL blood based biomarker BGB601 (partnered AXL ADC drug candidate) anti tumour pre-clinical data to be presented at AACR. Bergen, Norway, 13 April 2018 – BerGenBio ASA (OSE: BGBIO) announces that promising pre-clinical data demonstrating that selective … Read more
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. … Read more
Bergen, Norway, 10 April 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy in NSCLC, AML/MDS, TNBC and melanoma, announces that it has completed enrolment of the planned 22 patients into the first stage of its Phase II clinical trial … Read more
Bergen, Norway, 22 March 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the Company will be presenting an overview of the three ongoing phase II trials combining the Company’s selective AXL inhibitor bemcentinib with the anti-PD-1 therapy … Read more
Bergen, Norge, 15. mars 2017 – BerGenBio ASA (OSE:BGBIO), et onkologisk bioteknologiselskap i klinisk fase som utvikler ‘first-in-class’ hemmere av Axl kinase mot flere krefttyper, opplyser at lovende prekliniske data med BerGenBios ledende AXL-hemmer bemcentinib (tidligere BGB324) kommer til å bli presentert på American Association of Cancer Research (AACR) sitt årsmøte for 2018 i perioden … Read more
Bergen, Norway, 15 March 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with BerGenBio’s lead AXL inhibitor bemcentinib (formerly BGB324) will be featured at the 2018 American Association for Cancer Research (AACR) Annual Meeting on 14-18 April in Chicago, … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.